A Double-Blind, Randomized, Placebo-controlled Multicenter Trial of GRanulocyte-Macrophage Colony-stimulating Factor Administration to Decrease ICU Acquired Infections in Sepsis-induced ImmunoDepression
Phase of Trial: Phase III
Latest Information Update: 11 Sep 2016
At a glance
- Drugs Sargramostim (Primary)
- Indications Sepsis
- Focus Therapeutic Use
- Acronyms GRID
- 19 Jan 2016 Planned primary completion date changed from 1 Mar 2018 to 1 Sep 2018, as reported by ClinicalTrials.gov.
- 19 Jan 2016 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.
- 18 Feb 2015 New trial record